Updated review on benzimidazole derivatives as potential antihypertensive agents

Abstract

A growing number of researchers in the field of medicinal chemistry are focused on nitrogenous heterocyclic compounds. Benzimidazole scaffolds appear often in this group of heterocyclic compounds. Benzimidazole derivatives are important chemotherapeutic drugs because of their isostructural pharmacophore of naturally occurring active biomolecules. Many benzimidazole derivatives have been produced in the recent few decades, and many of these compounds have shown high bioactivity against a wide range of diseases and have bioavailability, safety, and stability profiles that are among the best in the industry. Here, we've included data on the antihypertensive properties of benzimidazole derivatives that have appeared in recent studies (2010–2022), along with a structure-activity link for each. Human studies are underway for a number of intriguing therapeutic candidates, and some of them will be authorized for use in clinical settings. In order to gather the information on proposed topic all the scientific search engines and publisher sites were used such as Google scholar, Science direct, Bentham science, PubChem, PubMed, Tayler and Francis, Hindawi, Springer nature, and ACS websites. The present review provides a detailed insight of benzimidazole derivatives reported as antihypertensive agents.